Bausch & Lomb Q3 Adj. EPS $0.34 Beats $0.22 Estimate, Sales $1.375B Beat $1.373B Estimate
Benzinga Newsdesk 3 weeks ago
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Bausch & Lomb (NYSE:BLCO) reported quarterly earnings of $0.34 per share which beat the analyst consensus estimate of $0.22 by 54.55 percent. This is a 88.89 percent increase over earnings of $0.18 per share from
Bausch & Lomb (NYSE:BLCO) reported quarterly earnings of $0.34 per share which beat the analyst consensus estimate of $0.22 by 54.55 percent. This is a 88.89 percent increase over earnings of $0.18 per share from the same period last year. The company reported quarterly sales of $1.375 billion which beat the analyst consensus estimate of $1.373 billion by 0.12 percent. This is a 7.34 percent increase over sales of $1.281 billion the same period last year.
More on BLCO
FDA & biotech Benzinga
Bausch + Lomb Post-Surgery Eye Pain Drug Misses Study Goal But Shows Early ReliefBausch + Lomb reports Phase 2 data for eye pain drug BL1332, showing early relief and strong safety despite missing its primary endpoint.

Benzinga
Bausch + Lomb Reports Phase 2 Results For BL1332; Primary Endpoint Missed, Exploratory Analyses Show Pain Relief And Faster Corneal HealingBoth BL1332 doses demonstrated numerically greater pain relief than vehicle across all primary, secondary and exploratory pain analyses; the primary endpoint at 24 hours was not metExploratory…
